|
Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors. |
|
|
Stock and Other Ownership Interests - Caremission; Medelis |
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MedImmune (Inst); Merck Serono (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Sirtex Medical (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Cerulean Pharma; Lilly; Pharmacyclics; Taiho Pharmaceutical; Vaccinex |
Consulting or Advisory Role - Celgene; Genentech; Lilly; Vaccinex |
Research Funding - Abbvie; Bayer; Biomarin; Celgene; Genentech; Halozyme; Merck/Schering Plough; Merrimack; Sanofi; Tekmira; Vaccinex; Verastem |
Travel, Accommodations, Expenses - Biomarin |
Other Relationship - Celgene |
|
|
|
Stock and Other Ownership Interests - Syndax |
Honoraria - Genentech; Symphony Evolution |
Consulting or Advisory Role - Nektar; Symphony Evolution |
Research Funding - Genentech/Roche (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Nektar |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
Consulting or Advisory Role - Amgen; Bayer; Bayer/Onyx; Boehringer Ingelheim; Celgene; Genentech/Roche; Marval Biosciences; Onyx |
Research Funding - Abbvie (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); MedImmune (Inst); MethylGene (Inst); OncoMed (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst) |